eptacog
Trade name: Novoseven
Biologicalexperimental
Recombinant factor VIIa (rfVIIa) is a form of blood factor VII that has been manufactured via recombinant technology. It is administered via an injection into a vein. It is used to treat bleeding episodes in people who have acquired hemophilia, among other indications. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
1
Earliest trial started Jul 23, 2018 (NCT03935334)
Timeline
Indications
Mechanism of action
- Coagulation factor VIISupplementation
F7 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRecombinant factor VIIa ↗
Also known as
- coagulation factor vii human
- coagulation factor vii (human)
- factor vii
- factor vii
- factor vii human
- factor vii (proconvertin)
- human coagulation factor vii
- proconvertin
- serum prothrombin conversion accelerator
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07136857 | Phase 2 | Oct 31, 2025 | Emory University |
| NCT07157423 | Phase 4 | Aug 26, 2025 | Novo Nordisk |
| NCT03935334 | Phase 3 | Jul 23, 2018 | AryoGen Pharmed Co. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AryoGen Pharmed Co. | For profit | 1 | 1 | 1 | 2018 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Novo Nordisk | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1